[Usefulness of perospirone for the prevention of nausea related to opioid administration].

Abstract

PURPOSE:

In our department, prochlorperazine, a D2 receptor antagonist, was previously administered to prevent nausea related to the introduction of opioids. However, we always had to consider extrapyramidal symptoms. Since August 2006, perospirone has been administered to all patients who have commenced oral opioid therapy, to prevent nausea. In this study, we investigated its usefulness in the prevention of nausea.

METHODS:

Perospirone (4 or 8 mg, once a day) was combined in all patients in whom opioid therapy was introduced with oxycodone at 10 mg/day. We retrospectively examined the presence or absence of nausea within 1 week.

RESULTS:

Oxycodone-related nausea occurred in 1 of 25 patients. There were no adverse reactions such as extrapyramidal symptoms.

CONCLUSION:

These results suggest the usefulness of perospirone for the prevention of nausea related to the intro- duction of opioids.

• Authors: Kinomi Yomiya, Naoki Matsuo, Shinichirou Okuyama
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 35 Issue 4 Pg. 625-8 (Apr 2008) ISSN: 0385-0684 [Print] Japan
• PMID: 18408431 (Publication Type: English Abstract, Journal Article)

Chemical References

• Analgesics, Opioid
• Isoindoles
• Thiazoles
• perospirone

Topics

• Aged
• Aged, 80 and over
• Analgesics, Opioid (administration & dosage, adverse effects)
• Female
• Humans
• Isoindoles (pharmacology)
• Male
• Middle Aged
• Nausea (prevention & control)
• Retrospective Studies
• Thiazoles (pharmacology)